valproic acid has been researched along with Apoplexy in 39 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder." | 8.87 | Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. ( Chuang, DM; Fessler, EB; Wang, ZF, 2011) |
| "Previous studies have shown the neuroprotective effects of the valproic acid (2-n-propylpentanoic acid, VPA) against ischemic stroke, but its effects on the ischemia-induced formation of astrogliosis and glial scar are still unknown." | 8.12 | Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke. ( Gao, X; Guo, Y; He, YY; Zeb, S; Zhang, HL; Zhou, XY; Zhu, YM, 2022) |
| "We sought to explore the effects of sodium valproate combined with lamotrigine on quality of life and serum inflammatory factors in patients with poststroke secondary epilepsy." | 7.96 | Effects of Sodium Valproate Combined with Lamotrigine on Quality of Life and Serum Inflammatory Factors in Patients with Poststroke Secondary Epilepsy. ( Guo, D; Hao, F; Li, X; Liu, X; Sun, J; Tang, W; Tao, S, 2020) |
| "We report a case of stroke in a child with acquired protein C deficiency receiving valproic acid (VPA)." | 7.70 | Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. ( Balasa, V; Degrauw, A; Fogelson, H; Gartside, P; Glauser, T; Gruppo, R, 2000) |
| "Acute ataxia is commonly the chief complaint among patients visiting the emergency department (ED)." | 5.72 | A Phenytoin-Induced Ataxia Mimicking a Stroke. ( Urushidani, S, 2022) |
| "Levetiracetam (LEV) is an AED that is neuroprotective in various neurologic disorders." | 5.51 | Levetiracetam administration is correlated with lower mortality in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: a retrospective study. ( Bao, XH; Wang, ZX; Xiong, H; Yuan, Y; Zhang, X; Zhang, Z; Zhao, DH; Zhao, XT, 2019) |
| "Overall, 1." | 5.42 | Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. ( Chan, L; Chi, NF; Chien, LN; Chiou, HY; Hu, CJ; Huang, YH; Kuan, YC, 2015) |
| "Acute treatment of stroke with histone deacetylase (HDAC) inhibitors has been shown to reduce ischemic cell damage; however, it is unclear whether delayed treatment with HDAC inhibitors will contribute to the brain repair and plasticity." | 5.38 | Valproic acid increases white matter repair and neurogenesis after stroke. ( Chen, C; Chopp, M; Cui, YS; Hozeska-Solgot, A; Jia, LF; Kassis, H; Liu, XS; Zhang, RL; Zhang, ZG, 2012) |
| "The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder." | 4.87 | Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. ( Chuang, DM; Fessler, EB; Wang, ZF, 2011) |
| "Previous studies have shown the neuroprotective effects of the valproic acid (2-n-propylpentanoic acid, VPA) against ischemic stroke, but its effects on the ischemia-induced formation of astrogliosis and glial scar are still unknown." | 4.12 | Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke. ( Gao, X; Guo, Y; He, YY; Zeb, S; Zhang, HL; Zhou, XY; Zhu, YM, 2022) |
| "We sought to explore the effects of sodium valproate combined with lamotrigine on quality of life and serum inflammatory factors in patients with poststroke secondary epilepsy." | 3.96 | Effects of Sodium Valproate Combined with Lamotrigine on Quality of Life and Serum Inflammatory Factors in Patients with Poststroke Secondary Epilepsy. ( Guo, D; Hao, F; Li, X; Liu, X; Sun, J; Tang, W; Tao, S, 2020) |
| "Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder." | 3.91 | Mood stabilisers and risk of stroke in bipolar disorder. ( Chang, CK; Chen, CC; Chen, PH; Kuo, CJ; Pan, CH; Su, SS; Tsai, SY, 2019) |
| "We report a case of stroke in a child with acquired protein C deficiency receiving valproic acid (VPA)." | 3.70 | Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. ( Balasa, V; Degrauw, A; Fogelson, H; Gartside, P; Glauser, T; Gruppo, R, 2000) |
| "Stroke is the leading cause of epilepsy in the elderly, ahead of degenerative diseases, tumors and head injuries." | 1.91 | Post-stroke seizures: risk factors and management after ischemic stroke. ( Derbali, H; Mansour, M; Messelmani, M; Mrissa, N; Mrissa, R; Ouerdiene, A; Zaouali, J, 2023) |
| "Specific antiseizure medications (ASM) would improve the outcome in post-stroke epilepsy (PSE)." | 1.72 | Efficacy and safety of antiseizure medication in post-stroke epilepsy. ( Groppa, S; Klimpe, S; Sandner, K; Stuckrad-Barre, SV; Uphaus, T; Winter, Y, 2022) |
| "Acute ataxia is commonly the chief complaint among patients visiting the emergency department (ED)." | 1.72 | A Phenytoin-Induced Ataxia Mimicking a Stroke. ( Urushidani, S, 2022) |
| "Carbamazepine was the second most common drug followed by lamotrigine and valproic acid." | 1.62 | Post-stroke epilepsy and antiepileptic drug use in men and women. ( Linnér, L; Loikas, D; Sundström, A; von Euler, M; Wettermark, B, 2021) |
| "Semiology of the most frequent seizures was motor focal in 82%, followed by focal motor with secondary bilateralization in 23%, focal discognitive in 13." | 1.51 | [Epilepsy in children with congenital hemiparesis secondary to perinatal ictus]. ( Alonso, X; Campistol, J; Escofet, C; Fons, C; Macaya, A; Revilla Orías, MD, 2019) |
| "Levetiracetam (LEV) is an AED that is neuroprotective in various neurologic disorders." | 1.51 | Levetiracetam administration is correlated with lower mortality in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: a retrospective study. ( Bao, XH; Wang, ZX; Xiong, H; Yuan, Y; Zhang, X; Zhang, Z; Zhao, DH; Zhao, XT, 2019) |
| "Carbamazepine was the most chosen antiepileptic drug for secondary prophylaxis, followed by valproate acid, and levetiracetam." | 1.48 | [A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan]. ( Abe, S; Fukuma, K; Higashida, K; Ihara, M; Nagatsuka, K; Okuno, Y; Tanaka, T; Tomari, S; Toyoda, K; Yamagami, H, 2018) |
| "New-onset stroke was seen in three cases (10%) of the control group and in two cases (6." | 1.46 | Clinical study on anti-epileptic drug with B vitamins for the treatment of epilepsy after stroke. ( Huang, HL; Wang, N; Xu, L; Yu, CY; Zhou, H, 2017) |
| "Hyperglycemia was induced by streptozotocin (STZ) injection 3 days before." | 1.42 | Valproic acid ameliorates ischemic brain injury in hyperglycemic rats with permanent middle cerebral occlusion. ( Abe, A; Aoki, J; Kimura, K; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Suda, S; Suzuki, K; Ueda, M, 2015) |
| "Overall, 1." | 1.42 | Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. ( Chan, L; Chi, NF; Chien, LN; Chiou, HY; Hu, CJ; Huang, YH; Kuan, YC, 2015) |
| " In addition, there appeared to be a dose-response relationship between stroke risk and PHT prescriptions." | 1.39 | Comparative stroke risk of antiepileptic drugs in patients with epilepsy. ( Hsieh, CY; Lai, EC; Lin, SJ; Yang, YH, 2013) |
| "Acute treatment of stroke with histone deacetylase (HDAC) inhibitors has been shown to reduce ischemic cell damage; however, it is unclear whether delayed treatment with HDAC inhibitors will contribute to the brain repair and plasticity." | 1.38 | Valproic acid increases white matter repair and neurogenesis after stroke. ( Chen, C; Chopp, M; Cui, YS; Hozeska-Solgot, A; Jia, LF; Kassis, H; Liu, XS; Zhang, RL; Zhang, ZG, 2012) |
| "Male rats underwent middle cerebral artery occlusion for 60 minutes followed by reperfusion for up to 14 days." | 1.38 | Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. ( Chibane, F; Chuang, DM; Fessler, EB; Leeds, P; Leng, Y; Munasinghe, J; Tsai, LK; Wang, Z, 2012) |
| "The pathophysiology of cerebral ischemia involves multiple mechanisms including neuroinflammation mediated by activated microglia and infiltrating macrophages/monocytes." | 1.34 | Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. ( Chen, PS; Chuang, DM; Hong, JS; Kim, HJ; Ren, M; Rowe, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 7 (17.95) | 29.6817 |
| 2010's | 23 (58.97) | 24.3611 |
| 2020's | 8 (20.51) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X | 1 |
| Zeb, S | 1 |
| He, YY | 1 |
| Guo, Y | 1 |
| Zhu, YM | 1 |
| Zhou, XY | 1 |
| Zhang, HL | 1 |
| Winter, Y | 1 |
| Uphaus, T | 1 |
| Sandner, K | 1 |
| Klimpe, S | 1 |
| Stuckrad-Barre, SV | 1 |
| Groppa, S | 1 |
| Urushidani, S | 1 |
| Revilla Orías, MD | 1 |
| Alonso, X | 1 |
| Campistol, J | 1 |
| Macaya, A | 1 |
| Escofet, C | 1 |
| Fons, C | 1 |
| Tao, S | 1 |
| Sun, J | 1 |
| Hao, F | 1 |
| Tang, W | 1 |
| Li, X | 2 |
| Guo, D | 1 |
| Liu, X | 2 |
| Langenbruch, L | 1 |
| Meuth, SG | 1 |
| Wiendl, H | 1 |
| Mesters, R | 1 |
| Möddel, G | 1 |
| Demyanenko, SV | 1 |
| Dzreyan, VA | 1 |
| Uzdensky, AB | 1 |
| Loikas, D | 1 |
| Linnér, L | 1 |
| Sundström, A | 1 |
| Wettermark, B | 1 |
| von Euler, M | 1 |
| Ouerdiene, A | 1 |
| Messelmani, M | 1 |
| Derbali, H | 1 |
| Mansour, M | 1 |
| Zaouali, J | 1 |
| Mrissa, N | 1 |
| Mrissa, R | 1 |
| Holder, SD | 1 |
| Zhou, H | 1 |
| Wang, N | 1 |
| Xu, L | 1 |
| Huang, HL | 1 |
| Yu, CY | 1 |
| Brookes, RL | 1 |
| Crichton, S | 1 |
| Wolfe, CDA | 1 |
| Yi, Q | 1 |
| Li, L | 1 |
| Hankey, GJ | 1 |
| Rothwell, PM | 1 |
| Markus, HS | 2 |
| Faggi, L | 1 |
| Pignataro, G | 1 |
| Parrella, E | 1 |
| Porrini, V | 1 |
| Vinciguerra, A | 1 |
| Cepparulo, P | 1 |
| Cuomo, O | 1 |
| Lanzillotta, A | 1 |
| Mota, M | 1 |
| Benarese, M | 1 |
| Tonin, P | 1 |
| Annunziato, L | 1 |
| Spano, P | 1 |
| Pizzi, M | 1 |
| Bolland, MJ | 1 |
| Avenell, A | 1 |
| Gamble, G | 1 |
| Grey, A | 1 |
| Higashida, K | 1 |
| Tanaka, T | 1 |
| Yamagami, H | 1 |
| Tomari, S | 1 |
| Fukuma, K | 1 |
| Okuno, Y | 1 |
| Abe, S | 1 |
| Nagatsuka, K | 1 |
| Toyoda, K | 1 |
| Ihara, M | 1 |
| Thusius, N | 1 |
| Romanowicz, M | 1 |
| Mlynek, K | 1 |
| Sola, C | 1 |
| Chen, PH | 1 |
| Tsai, SY | 1 |
| Pan, CH | 1 |
| Chang, CK | 1 |
| Su, SS | 1 |
| Chen, CC | 1 |
| Kuo, CJ | 1 |
| Zhang, Z | 1 |
| Zhao, DH | 1 |
| Zhao, XT | 1 |
| Zhang, X | 1 |
| Xiong, H | 1 |
| Bao, XH | 1 |
| Yuan, Y | 1 |
| Wang, ZX | 1 |
| Suda, S | 3 |
| Katsura, K | 1 |
| Kanamaru, T | 1 |
| Saito, M | 2 |
| Katayama, Y | 3 |
| Katsura, KI | 1 |
| Kamiya, N | 1 |
| Dregan, A | 1 |
| Charlton, J | 1 |
| Wolfe, CD | 1 |
| Gulliford, MC | 1 |
| Ueda, M | 1 |
| Nito, C | 1 |
| Nishiyama, Y | 1 |
| Okubo, S | 1 |
| Abe, A | 1 |
| Aoki, J | 1 |
| Suzuki, K | 1 |
| Sakamoto, Y | 1 |
| Kimura, K | 1 |
| Özdemir, HH | 1 |
| Müngen, B | 1 |
| İlhan, S | 1 |
| Huang, YH | 1 |
| Chi, NF | 1 |
| Kuan, YC | 1 |
| Chan, L | 1 |
| Hu, CJ | 1 |
| Chiou, HY | 1 |
| Chien, LN | 1 |
| Aebischer, B | 1 |
| Elsig, S | 1 |
| Taeymans, J | 1 |
| Pomp, S | 1 |
| Kuhness, D | 1 |
| Barcaro, G | 1 |
| Sementa, L | 1 |
| Mankad, V | 1 |
| Fortunelli, A | 1 |
| Sterrer, M | 1 |
| Netzer, FP | 1 |
| Surnev, S | 1 |
| Schmieder, AH | 1 |
| Caruthers, SD | 1 |
| Keupp, J | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Lowe, J | 1 |
| Wodarcyk, AJ | 1 |
| Floyd, KT | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Swager, SA | 1 |
| Chadwick, JA | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Janssen, PM | 1 |
| Rafael-Fortney, JA | 1 |
| Alcalay, RN | 1 |
| Levy, OA | 1 |
| Wolf, P | 1 |
| Oliva, P | 1 |
| Zhang, XK | 1 |
| Waters, CH | 1 |
| Fahn, S | 1 |
| Kang, U | 1 |
| Liong, C | 1 |
| Ford, B | 1 |
| Mazzoni, P | 1 |
| Kuo, S | 1 |
| Johnson, A | 1 |
| Xiong, L | 1 |
| Rouleau, GA | 1 |
| Chung, W | 1 |
| Marder, KS | 1 |
| Gan-Or, Z | 1 |
| Kamei, K | 1 |
| Terao, T | 1 |
| Hatano, K | 1 |
| Kodama, K | 1 |
| Shirahama, M | 1 |
| Sakai, A | 1 |
| Hirakawa, H | 1 |
| Mizokami, Y | 1 |
| Shiotsuki, I | 1 |
| Ishii, N | 1 |
| Inoue, Y | 1 |
| Akboga, MK | 1 |
| Yayla, C | 1 |
| Balci, KG | 1 |
| Ozeke, O | 1 |
| Maden, O | 1 |
| Kisacik, H | 1 |
| Temizhan, A | 1 |
| Aydogdu, S | 1 |
| Zhu, J | 2 |
| Ying, SH | 1 |
| Feng, MG | 1 |
| Zhang, XG | 1 |
| Li, H | 1 |
| Wang, L | 1 |
| Hao, YY | 1 |
| Liang, GD | 1 |
| Ma, YH | 1 |
| Yang, GS | 1 |
| Hu, JH | 1 |
| Pfeifer, L | 1 |
| Goertz, RS | 1 |
| Neurath, MF | 1 |
| Strobel, D | 1 |
| Wildner, D | 1 |
| Lin, JT | 1 |
| Yang, XN | 1 |
| Zhong, WZ | 1 |
| Liao, RQ | 1 |
| Dong, S | 1 |
| Nie, Q | 1 |
| Weng, SX | 1 |
| Fang, XJ | 1 |
| Zheng, JY | 1 |
| Wu, YL | 1 |
| Řezanka, T | 1 |
| Kaineder, K | 1 |
| Mezricky, D | 1 |
| Řezanka, M | 1 |
| Bišová, K | 1 |
| Zachleder, V | 1 |
| Vítová, M | 1 |
| Rinker, JA | 1 |
| Marshall, SA | 1 |
| Mazzone, CM | 1 |
| Lowery-Gionta, EG | 1 |
| Gulati, V | 1 |
| Pleil, KE | 1 |
| Kash, TL | 1 |
| Navarro, M | 1 |
| Thiele, TE | 1 |
| Zhang, Y | 1 |
| Huang, Y | 1 |
| Jin, Z | 1 |
| Li, B | 1 |
| Xu, P | 1 |
| Huang, P | 1 |
| Liu, C | 1 |
| Fokdal, L | 1 |
| Sturdza, A | 1 |
| Mazeron, R | 1 |
| Haie-Meder, C | 1 |
| Tan, LT | 1 |
| Gillham, C | 1 |
| Šegedin, B | 1 |
| Jürgenliemk-Schultz, I | 1 |
| Kirisits, C | 1 |
| Hoskin, P | 1 |
| Pötter, R | 1 |
| Lindegaard, JC | 1 |
| Tanderup, K | 1 |
| Levin, DE | 1 |
| Schmitz, AJ | 1 |
| Hines, SM | 1 |
| Hines, KJ | 1 |
| Tucker, MJ | 1 |
| Brewer, SH | 1 |
| Fenlon, EE | 1 |
| Álvarez-Pérez, S | 1 |
| Blanco, JL | 1 |
| Peláez, T | 1 |
| Martínez-Nevado, E | 1 |
| García, ME | 1 |
| Puckerin, AA | 1 |
| Chang, DD | 1 |
| Subramanyam, P | 1 |
| Colecraft, HM | 1 |
| Dogan, H | 1 |
| Coteli, E | 1 |
| Karatas, F | 1 |
| Ceylan, O | 1 |
| Sahin, MD | 1 |
| Akdamar, G | 1 |
| Kryczyk, A | 1 |
| Żmudzki, P | 1 |
| Hubicka, U | 1 |
| Giovannelli, D | 1 |
| Chung, M | 1 |
| Staley, J | 1 |
| Starovoytov, V | 1 |
| Le Bris, N | 1 |
| Vetriani, C | 1 |
| Chen, W | 1 |
| Wu, L | 1 |
| Shen, Y | 1 |
| Liang, Y | 1 |
| Tan, H | 1 |
| Yang, Y | 1 |
| Liu, Q | 1 |
| Wang, M | 1 |
| Liu, L | 1 |
| Wang, X | 1 |
| Liu, B | 1 |
| Liu, GH | 1 |
| Zhu, YJ | 1 |
| Wang, JP | 1 |
| Che, JM | 1 |
| Chen, QQ | 1 |
| Chen, Z | 1 |
| Maucksch, U | 1 |
| Runge, R | 1 |
| Wunderlich, G | 1 |
| Freudenberg, R | 1 |
| Naumann, A | 1 |
| Kotzerke, J | 1 |
| Lippi, G | 1 |
| Targher, G | 1 |
| Franchini, M | 1 |
| Tsai, LK | 2 |
| Wang, Z | 2 |
| Munasinghe, J | 2 |
| Leng, Y | 2 |
| Leeds, P | 2 |
| Chuang, DM | 5 |
| Wang, ZF | 1 |
| Fessler, EB | 2 |
| Chabwine, JN | 1 |
| Rossetti, AR | 1 |
| Hirt, L | 1 |
| Kuntzer, T | 1 |
| Schluep, M | 1 |
| Michel, P | 1 |
| Démonet, JF | 1 |
| du Pasquier, RA | 1 |
| Vingerhoets, FG | 1 |
| Liu, XS | 1 |
| Chopp, M | 1 |
| Kassis, H | 1 |
| Jia, LF | 1 |
| Hozeska-Solgot, A | 1 |
| Zhang, RL | 1 |
| Chen, C | 1 |
| Cui, YS | 1 |
| Zhang, ZG | 1 |
| Chibane, F | 1 |
| Hsieh, CY | 1 |
| Lai, EC | 1 |
| Yang, YH | 1 |
| Lin, SJ | 1 |
| Kim, HJ | 1 |
| Rowe, M | 1 |
| Ren, M | 1 |
| Hong, JS | 1 |
| Chen, PS | 1 |
| Arnold, G | 1 |
| Schuh-Hofer, S | 1 |
| da Rocha, FF | 1 |
| Correa, H | 1 |
| Teixeira, AL | 1 |
| Dervaux, A | 1 |
| Levasseur, M | 1 |
| Alla, P | 1 |
| Philip, N | 1 |
| Azulay, JP | 1 |
| Attarian, S | 1 |
| Pouget, J | 1 |
| Gruppo, R | 1 |
| Degrauw, A | 1 |
| Fogelson, H | 1 |
| Glauser, T | 1 |
| Balasa, V | 1 |
| Gartside, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
5 reviews available for valproic acid and Apoplexy
| Article | Year |
|---|---|
Psychotic and Bipolar Disorders: Bipolar Disorder.
Topics: Antimanic Agents; Bipolar Disorder; Cardiovascular Diseases; Chronic Pain; Comorbidity; Family Pract | 2017 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; A | 2016 |
Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Disease Models, Animal; Humans; Lamotrigine; Lithiu | 2011 |
The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials.
Topics: Affect; Animals; Antimanic Agents; Apoptosis; Excitatory Amino Acid Agonists; Humans; Lithium; N-Met | 2005 |
[Comorbidities in migraine patients].
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants; Anxiety Disorders; Carotid Artery, | 2007 |
1 trial available for valproic acid and Apoplexy
| Article | Year |
|---|---|
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Brain Ischemia; Disease-Free Survival; Female; Follow-Up S | 2018 |
33 other studies available for valproic acid and Apoplexy
| Article | Year |
|---|---|
Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke.
Topics: Animals; Astrocytes; Brain Ischemia; Glial Fibrillary Acidic Protein; Gliosis; Histones; Ischemic St | 2022 |
Efficacy and safety of antiseizure medication in post-stroke epilepsy.
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy; Humans; Lacosamide; Lamotrigine; Levetiracetam; Seiz | 2022 |
A Phenytoin-Induced Ataxia Mimicking a Stroke.
Topics: Ataxia; Carbamazepine; Female; Humans; Middle Aged; Phenytoin; Stroke; Valproic Acid | 2022 |
[Epilepsy in children with congenital hemiparesis secondary to perinatal ictus].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsy; Female; Humans; Infan | 2019 |
Effects of Sodium Valproate Combined with Lamotrigine on Quality of Life and Serum Inflammatory Factors in Patients with Poststroke Secondary Epilepsy.
Topics: Aged; Anticonvulsants; Biomarkers; Brain; Case-Control Studies; Down-Regulation; Drug Therapy, Combi | 2020 |
Clinically relevant interaction of rivaroxaban and valproic acid - A case report.
Topics: Administration, Oral; Adult; Anticoagulants; Anticonvulsants; Atrial Fibrillation; Factor Xa Inhibit | 2020 |
Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate.
Topics: Animals; Cerebral Cortex; Gene Expression; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Hi | 2020 |
Post-stroke epilepsy and antiepileptic drug use in men and women.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigin | 2021 |
Post-stroke seizures: risk factors and management after ischemic stroke.
Topics: Aged; Epilepsy; Female; Humans; Infarction, Middle Cerebral Artery; Ischemic Stroke; Male; Middle Ag | 2023 |
Clinical study on anti-epileptic drug with B vitamins for the treatment of epilepsy after stroke.
Topics: Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Stroke; Valproic Acid; Vi | 2017 |
Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke.
Topics: Acetylation; Animals; Bcl-2-Like Protein 11; Disease Models, Animal; Drug Synergism; Histone Deacety | 2018 |
Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to pre
Topics: Adult; Bone Density; Bone Remodeling; Brain Ischemia; Dietary Supplements; Epilepsy; Humans; Hyperpa | 2018 |
[A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan].
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Japan; Levetiracetam; Male; Piracetam; Sei | 2018 |
Prolonged Psychosis Associated with Left Insular Stroke: Talking to God in the Walls.
Topics: Aged; Antimanic Agents; Antipsychotic Agents; Cerebral Cortex; Electroencephalography; Hallucination | 2018 |
Mood stabilisers and risk of stroke in bipolar disorder.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cross-O | 2019 |
Levetiracetam administration is correlated with lower mortality in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: a retrospective study.
Topics: Acidosis, Lactic; Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Female; Human | 2019 |
Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Brain Ischemia; Disease Models, Animal; In Situ Nic | 2013 |
Valproic acid enhances the effect of bone marrow-derived mononuclear cells in a rat ischemic stroke model.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Brain Ischemia; Combined Modality Therapy; | 2014 |
Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study.
Topics: Aged; Aged, 80 and over; Bias; Brain Ischemia; Case-Control Studies; Databases, Factual; Electronic | 2014 |
Valproic acid ameliorates ischemic brain injury in hyperglycemic rats with permanent middle cerebral occlusion.
Topics: Animals; Blood Glucose; Brain; Brain Ischemia; Hyperglycemia; Infarction, Middle Cerebral Artery; Ma | 2015 |
Evaluation of the efficacy of sodium valproate in convulsive status epilepticus following to ıschemic stroke.
Topics: Administration, Intravenous; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; | 2015 |
Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Cohort Studies; Female; Humans; Male | 2015 |
Migraine, valproic acid, and lipoprotein(a).
Topics: Analgesics; Child; Humans; Lipoprotein(a); Migraine Disorders; Risk Factors; Stroke; Valproic Acid | 2009 |
Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model.
Topics: Animals; Cell Movement; Infarction, Middle Cerebral Artery; Lithium; Mesenchymal Stem Cell Transplan | 2011 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Valproic acid increases white matter repair and neurogenesis after stroke.
Topics: Animals; Brain; Histone Deacetylase Inhibitors; Immunohistochemistry; In Situ Nick-End Labeling; Mal | 2012 |
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.
Topics: Animals; Anticonvulsants; Blotting, Western; Brain Ischemia; Cerebral Infarction; Hypoxia-Inducible | 2012 |
Comparative stroke risk of antiepileptic drugs in patients with epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Male | 2013 |
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Topics: Animals; Anti-Inflammatory Agents; Brain; Brain Ischemia; Butyrates; CD11b Antigen; Cerebral Infarct | 2007 |
A successful outcome with valproic acid in a case of mania secondary to stroke of the right frontal lobe.
Topics: Anticonvulsants; Bipolar Disorder; Female; Frontal Lobe; Humans; Middle Aged; Stroke; Treatment Outc | 2008 |
Risperidone and valproate for mania following stroke.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Humans; Male; Middle Aged; Risperidone; Str | 2008 |
[Epilepsy in an adult with chromosome 22q11 micro-deletion].
Topics: Adult; Anticonvulsants; Atrophy; Brain; Chromosome Deletion; Chromosomes, Human, Pair 22; DiGeorge S | 1999 |
Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke.
Topics: Anticonvulsants; Antithrombins; Child; Child, Preschool; Female; Fibrinogen; Humans; Infant; Platele | 2000 |